Article
Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.
Genomics - 1 Jul 2023
Chen Hefeng, Ge Mengxi, Zhang Fuchuang, Xing Yishi, Yu Shicheng, Chen Chunzhu, Zhang Hougang, Wang Xiaoyong, Gao Xing, Chen Fangtao, Chen Peilin, Zhang Dadong, Zhan Qiong, Zhu Youcai
Abstract excerpt
Programmed death-ligand 1 (PD-L1) has been widely used in immunotherapy evaluation of patients with non-small cell lung cancer (NSCLC). However, the effect is not particularly ideal, and the association between PD-L1 and genetic alterations requires more exploration. Here, we performed targeted next-generation sequencing and PD-L1 immunohistochemistry (IHC) testing for PD-L1 expression on both tumor cells (TCs)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.